Congress Instructs FDA On Nanotech Work, But Mum On Regulations
This article was originally published in The Tan Sheet
Executive Summary
The recently passed user fee reauthorization includes a provision that directs FDA to evaluate nano-engineered products’ potential benefits and safety. Friends of the Earth says nanotech products are available “prematurely … without having enough safety data.”
You may also be interested in...
House, Senate Differ In Treating FDA China Syndrome
Appropriators in the House and Senate endorse FDA’s plan to spend $10 million more on inspections in China in 2013, but only the Senate approves increasing the agency’s budget to cover the costs. FDA’s request for China inspections includes $5.6 million for inspections at drug facilities.
Senate Appropriators Call For Botanical Identity Testing Guidance
A Senate FDA appropriation report says the guidance would enhance the agency’s ability to inspect and assess industry practices for manufacturing botanical dietary supplements. A National Center for Natural Products Research official says most botanical ingredients lack standard identity tests.
FDA Nanotech Guidance Takes Small Step Forward
FDA initiates a dialogue with industry on nanotechnology in regulated products via a broad draft guidance document.